Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate in Obese Subjects With Dyslipidemia
NCT00231621Phase 3Terminated
- Sponsor
- Johnson & Johnson
- Start
- May 2001
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of topiramate in obesity and hypertriglyceridemia (3 arms), sponsored by Johnson & Johnson. Primary endpoints: Percent change in body weight from baseline to Week 60 and Percent change in fasting serum triglycerides from baseline to Week 60. Started May 2001; status: terminated.
02
Drugs
topiramate
03
Conditions
obesityhypertriglyceridemia
Beyond the preview
Go deeper on NCT00231621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231621.